Feature | April 16, 2014| Dave Fornell

Federal Court Orders Injunction on U.S. Sales of Medtronic CoreValve

Medtronic plans to appeal court ruling

Corevalve beats surgery, ACC 2014, TAVR vs surgery, Edwards lawsuit
April 16, 2014 — The U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's CoreValve transcatheter aortic valve replacement (TAVR) system in the United States. The court ordered the injunction April 10, which will go into effect the Week of April 21. 
 
At Medtronic's request, the Federal District Court agreed to postpone the implementation of the order for seven business days to allow Medtronic to seek prompt relief from the Federal Circuit Court of Appeals. Medtronic is appealing the court's injunction, and intends to ask the Federal Circuit Court of Appeals to prevent it from going into effect until it determines if the injunction was properly issued. 
 
The decision stems from a federal jury decision in 2010 that CoreValve willfully infringed on patent use for the Edwards Lifesciences Corp. U.S. Andersen transcatheter aortic valve replacement patent. 
 
At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. The companies are to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve to make a clinical judgment as to which device to implant (CoreValve or the Edwards’ Sapien device) free from the limitations of the injunction. The court stated that CoreValve is a “safer device, and that patients in whom it is implanted have better outcomes with a lower risk of death.” 
 
Medtronic said the ruling has no impact on the sale or marketing of CoreValve outside of the United States or the use of CoreValve in the current U.S. clinical trials.
 
Edwards initiated this case in 2008. On April 1, 2010, a federal jury found Medtronic willfully infringed Edwards' U.S. Andersen patent and awarded damages. In November 2012, the U.S. Court of Appeals for the Federal Circuit affirmed the jury decision. In October 2013, the U.S. Supreme Court declined to hear Medtronic's appeal.
 
The patent involved in this suit is part of the Andersen family of patents. The U.S. Andersen patent was issued in 1995. A petition has been filed with the U.S. Patent and Trademark Office to extend this patent into early 2016. In a separate case, a federal jury in January found that Medtronic CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter heart valve patent, and awarded damages to Edwards in that trial.
 
The Edwards’ Sapien TAVR system was the first to gain U.S. Food and Drug Administration (FDA) clearance in November 2011. The Medtronic CoreValve gained FDA approval this past January as the second TAVR device on the U.S. market. Many observers view the lawsuits by Edwards as a way to prevent competition in the U.S. market, similar to the suits and counter suits involved with drug-eluting stent manufactures in the United States over the past decade. Edwards filed similar suits in Europe after both valves gained market clearance there. Those suits have been ongoing for years.
 
The CoreValve System received FDA approval in January for patients at extreme risk for surgical valve replacement. Prior to that date, CoreValve therapy was available to extreme risk patients who were eligible to participate in the U.S. clinical trial. The CoreValve System is not yet approved in the U.S. for other patient groups.
 
In clinical trial data, the CoreValve appears to have better outcomes than that of the Sapien valve. At the American College of Cardiology (ACC) annual meeting in March, late-breaking trial data stated that the CoreValve actually out-performed surgical valve replacement despite the inexperience of the CoreValve operators with the device. The CoreValve U.S. pivotal high-risk patient trial showed the Medtronic self-expanding CoreValve device had a 26 percent survival benefit above the surgical valve implant patients. In the same patient population, the Edwards Sapien was found to be equal to surgery, but was not superior to surgery.
 
For more information: www.edwards.com, www.medtronic.com
 

Related Content

Stent graft, computational fluid dynamics, CFD, stent engineering

In this vector velocity model, brighter colors indicate blood flow acceleration as it passes through a bifurcation. Computation fluid dynamic modeling provides insight on blood flow through and near the walls of the stent graft. Image courtesy of Sanford Health

News | Cath Lab| August 27, 2015
August 27, 2015 — The use of computational fluid dynamics (CFD) modeling has been used for years to better engineer l
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in

Mitral regurgitation viewed under color Doppler. Image courtesy of Toshiba.

Feature | Heart Valve Repair| August 26, 2015
August 25, 2015 — Medtronic announced it entered a definitive agreement to acquire Twelve Inc., a start–up medical de
NuCART, CompView Medical, mobile boom system, cath lab, hybrid OR
Technology | Cath Lab| August 21, 2015
August 21, 2015 — CompView Medical announced the release of the NuCART, a turn-key, all-in-one mobile boom system wit
Corindus, Corpath, radiation dose monitoring, cath lab, vascular robotic system

The Corindus Corpath vascular robotic system.

Technology | Radiation Dose Management| August 19, 2015
Corindus Vascular Robotics Inc. and Unfors RaySafe Inc., a Fluke Biomedical Company, announced a distribution agreement...
Medtronic, CoreValve Evolut R, Loyola University Medical Center, first in Illinois, SURTAVI, EUS
News | Heart Valve Repair| August 19, 2015
Loyola University Medical Center is the first center in Illinois to implant the CoreValve Evolut R percutaneous aortic...
Sunshine Heart, COUNTER HF pivotal study, resumes enrollment, C-Pulse, FDA
News | Heart Failure| August 18, 2015
Sunshine Heart Inc. announced an update in late July on its COUNTER HF U.S. pivotal study for the C-Pulse Heart Assist...
corpath, corindus, robotic PCI, robots in the cath lab

The Corindus CorPath robotic system enables precise catheter manipulation in PCI procedures outside of the the radiation field. Buffalo General Medical Center, Buffalo, N.Y

Feature | Robotic Systems| August 17, 2015 | Dave Fornell
In the current healthcare economic climate of evaluating “nice vs.
CMS, additional participants, Bundled Payments for Care Improvement initiative, Medicare, eipsodes of care
News | Business| August 17, 2015
The Centers for Medicare & Medicaid Service (CMS) announced that over 2,100 healthcare facilities have agreed to...
global interventional cardiology devices market, worth, Grand View Research, stents, catheters
News | Cath Lab| August 17, 2015
The global interventional cardiology devices market is expected to reach $25.16 billion by 2020, according to a new...
Overlay Init